BRCA2 and breast cancer: Hormone receptor-positive BC (regardless of the BRCA1/BRCA2 mutation status) is currently considered a cancer with a favorable prognosis, allowing the omission of adjuvant chemotherapy, shorter course of adjuvant hormonal treatment (no longer than five years), and other “de-escalation” approaches.